• (PLX AI) – Calliditas shares fell 9% after SEB cut the stock to hold from buy, turning more cautious.
  • • Price target cut to SEK 75 from SEK 145
  • • An unfavorable distribution deal, a poorly timed capital raise, and the decisions of both the FDA and EMA to assess Nefecon in a standard review, instead of the earlier Priority/Accelerated review have flipped our previously optimistic view to one of caution, SEB said
  • • Now there is significant risk across a range of issues: SEB

Quelle: PLX AI